Sonoma pharmaceuticals, inc. (SNOA)
Income statement / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10
Product

-

-

-

-

-

-

-

-

-

-

-

-

7,704

6,742

7,572

8,077

11,800

12,062

10,734

9,939

5,254

5,230

6,610

7,210

11,175

11,380

11,814

12,897

13,334

13,182

12,588

11,494

11,005

10,505

9,491

8,826

0

0

0

Product licensing fees and royalties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

231

1,285

1,796

2,454

3,056

6,655

6,729

6,129

5,513

2,057

2,130

2,107

1,686

1,182

574

0

-

0

0

-

-

-

-

-

Service

-

-

-

-

-

-

-

-

-

-

-

-

844

884

971

1,061

1,112

1,074

954

859

879

904

949

945

857

826

852

869

875

885

896

891

911

1,028

939

928

0

0

0

Total revenues

18,739

19,341

19,312

18,970

18,243

17,806

17,192

16,658

17,031

15,549

14,022

12,825

7,949

7,071

8,327

9,369

14,197

14,932

14,142

13,854

12,788

12,863

13,688

13,668

14,089

14,336

14,773

15,452

15,468

14,718

13,855

12,744

11,706

0

0

-

0

-

-

Total cost of revenues

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Product

-

-

-

-

-

-

-

-

-

-

-

-

5,262

5,637

5,796

5,840

6,885

6,451

6,102

5,908

5,370

4,976

4,811

4,510

4,237

4,120

4,009

3,976

4,025

3,876

3,452

3,254

2,832

3,000

2,970

2,876

0

0

0

Service

-

-

-

-

-

-

-

-

-

-

-

-

734

732

775

881

900

868

785

658

741

757

774

761

650

652

705

733

753

771

754

776

763

821

759

737

0

0

0

Total cost of revenues

0

0

0

-

0

0

0

-

0

0

-

-

5,996

6,369

6,571

6,721

7,785

7,319

6,887

6,566

6,111

5,733

5,585

5,271

4,887

4,772

4,714

4,709

4,778

4,647

4,206

4,030

3,595

3,821

3,729

3,613

0

0

0

Gross profit

8,694

9,383

9,516

8,880

8,337

7,858

7,279

7,310

7,923

7,261

6,449

5,668

1,953

702

1,756

2,648

6,412

7,613

7,255

7,288

6,677

7,130

8,103

8,397

9,202

9,564

10,059

10,743

10,690

10,071

9,649

8,714

8,509

7,806

6,701

6,141

0

0

0

Operating expenses
Research and development

1,183

1,386

1,506

1,518

1,667

1,565

1,543

1,575

1,449

1,587

1,598

1,576

1,667

1,666

1,699

1,806

1,739

1,620

1,561

1,533

1,881

2,289

2,819

2,887

2,834

2,568

2,198

2,223

2,030

2,030

2,077

1,981

2,135

2,093

2,086

2,046

0

0

0

Selling, general and administrative

14,129

15,983

17,446

18,620

19,973

20,446

20,094

19,924

18,828

18,393

17,699

17,066

16,702

16,076

15,969

15,556

14,683

13,763

13,150

12,414

11,911

11,553

11,723

11,561

11,693

11,455

11,866

11,894

12,117

13,172

12,516

13,200

12,762

11,825

11,742

11,600

0

0

0

Total operating expenses

15,312

17,369

18,952

20,138

21,640

22,011

21,637

21,499

20,277

19,980

19,297

18,642

18,369

17,742

17,668

17,362

16,422

15,383

14,711

13,947

13,792

13,842

14,542

14,448

14,527

14,023

14,064

14,117

14,147

15,202

14,593

15,181

14,897

13,918

13,828

13,646

0

0

0

Loss from operations

-6,618

-7,986

-9,436

-11,258

-13,303

-14,153

-14,358

-14,189

-12,354

-12,719

-12,848

-12,974

-16,416

-17,040

-15,912

-14,714

-10,010

-7,770

-7,456

-6,659

-7,115

-6,712

-6,439

-6,051

-5,325

-4,459

-4,005

-3,374

-3,457

-5,131

-4,944

-6,467

-6,388

-6,112

-7,127

-7,505

0

0

0

Interest expense

20

26

31

33

35

39

42

40

32

21

12

3

4

4

4

3

0

0

0

3

6

624

811

1,058

1,320

977

1,069

1,107

1,122

1,107

1,057

931

802

651

509

406

0

0

0

Interest income

168

172

177

190

312

289

260

258

99

91

74

22

9

3

3

2

2

2

0

-

0

0

-

1

5

6

7

7

4

4

4

4

3

4

4

3

0

0

0

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax expense

-

-

-

-

-

-

-

-

-

-

-

-4,268

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-8,669

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income from discontinued operations (net of tax) (Note 4)

-

-

-

-

-

-

-

-

-

-

-

17,943

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss due to change in fair value of common stock (See Note 3)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

Gain due to change in fair value of derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

-

-

-

-

-

(Loss) gain due to change in fair value of derivative instruments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Other expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

146

133

125

60

70

145

217

307

277

259

175

0

0

0

Loss on impairment of investment held at cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on impairment of investment held at cost (See Note 3)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other (expense) income

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain due to change in fair value of common stock (See Note 10)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,357

493

-1,074

0

-

0

0

-

-

-

-

-

-

-

-

-

Gain due to change in fair value of derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11

176

851

1,627

3,164

1,432

753

-88

-1,566

-84

-481

0

-

0

0

-

-

-

-

-

-

0

-

-

Other income (expense), net

-

-

-349

-

-

-

-88

-307

-437

-165

-153

18

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of assets (Note 4)

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-4,794

-6,008

-7,625

-11,798

-13,339

-14,228

-14,278

-14,328

-12,002

7,413

8,334

9,274

8,801

-10,576

-10,390

-10,162

-8,753

-11,518

-10,473

-8,203

755

6,058

5,377

3,735

-6,167

-7,468

-7,588

-5,431

-4,754

-5,389

-4,709

-7,329

-7,255

-6,938

-7,748

-7,948

0

0

0

Net (loss) income per share: basic - Continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

0.18

-0.63

-0.76

-

-1.28

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income per share: basic - Discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

3.66

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share: basic and diluted - Discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

0.17

0.15

-

0.32

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock deemed dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

0

-

-

-

-

Preferred stock deemed dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

-

-

-

-

-

Net income (loss) available to common shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,493

-6,595

0

0

-

0

-

0

-

-

-

-

Net income (loss) per share: basic

-

-

0.54

-

-

-

-4.99

-

-0.73

-0.67

-

-

3.84

-0.46

-0.61

-

-0.96

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income per share: diluted - Continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

0.18

-

-

-

-1.28

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income per share: diluted - Discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

3.66

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share: diluted - Discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.32

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share: diluted

-

-

0.54

-

-

-

-4.99

-

-

-

-

-

3.84

-

-

-

-0.96

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average number of shares used in per share calculations: basic

-

-

1,316

-

-

-

693

-

-

-

-

-

4,225

-

-

-

3,293

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26,431

-

-

Weighted-average number of shares used in per share calculations: diluted

-

-

1,336

-

-

-

693

-

-

-

-

-

4,228

-

-

-

3,293

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss available to common shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Net loss per share: basic and diluted

-0.72

-0.91

-

-

-2.37

-3.93

-

-

-

-

-0.82

-

-

-

-

-

-

-0.54

-0.77

-0.07

-0.69

-0.08

-0.01

-

-0.09

-0.21

-0.26

-

-0.37

-0.33

-0.14

-1.67

-0.09

-0.03

-0.08

-0.07

-0.08

-0.06

-0.09

Weighted-average number of shares used in per common share calculations: basic and diluted

1,500

1,317

-

-

971

718

-

-10,987

4,392

4,313

4,294

-

-

4,202

4,198

-

-

3,251

3

-25,410

8,600

8,503

8,346

-

6

6

6

-

5,126

4

4

-64

27

26

26

-

-

-

-

Other comprehensive loss
Basic and diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26,321

26,215

Net loss

-4,794

-6,008

-7,625

-11,798

-13,339

-14,228

-14,278

-14,328

-12,002

7,413

8,334

9,274

8,801

-10,576

-10,390

-10,162

-8,753

-11,518

-10,473

-8,203

755

6,058

5,377

3,735

-6,167

-7,468

-7,588

-5,431

-4,754

-5,389

-4,709

-7,329

-7,255

-6,938

-7,748

-7,948

0

0

0

Foreign currency translation adjustments

985

430

943

374

-18

-104

-499

203

271

232

109

-324

-772

-424

-509

-347

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency translation adjustments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

1

-23

83

62

59

-12

-305

-152

-144

-77

222

87

0

0

0

Comprehensive loss

0

0

0

-

0

0

0

-

0

0

-

-

0

0

0

-

0

0

0

-

451

5,964

5,406

3,657

-6,166

-7,491

-7,505

-5,369

-4,695

-5,401

-5,014

-7,481

-7,399

-7,015

-7,526

-7,861

0

0

0

Product [Member]
Total revenues

17,584

18,248

18,171

17,881

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost of revenues

0

0

0

-

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Service [Member]
Total revenues

1,155

1,093

1,141

1,089

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost of revenues

0

0

0

-

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-